PA
BIO icon

Procyon Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Procyon Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-354
Closed -$206K – 249
2020
Q4 		$206K Sell
354
-123
-26% -$70K 0.1% 220
2020
Q3 		$246K Sell
477
-4
-0.8% -$2.03K 0.14% 169
2020
Q2 		$217K Sell
481
-206
-30% -$90.9K 0.12% 178
2020
Q1 		$241K Hold
687
– – 0.16% 128
2019
Q4 		$254K Buy
+687
New +$242K 0.16% 130

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Procyon Advisors's BIO Position: Q1 2021 in Review

Procyon Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 354 shares — an estimated $206K sold.

Procyon Advisors first reported a position in BIO in Q4 2019 and held it in 5 quarters. The position peaked at $254K in Q4 2019. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

  • Procyon Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
  • Procyon Advisors sold 354 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $206K.
  • Procyon Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 5 quarters.
  • Procyon Advisors's Bio-Rad Laboratories Class A position peaked at $254K in Q4 2019.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on Procyon Advisors's 13F filing for Q1 2021, filed 29 Apr 2021.